MedTrace Logo

Switching Medication to Treat Schizophrenia

NCT00044655 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 219

Last updated 2026-05-15

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.

Conditions

Interventions

DRUG

Risperidone

As prescribed by routine prescriber (not dictated by study protocol)

DRUG

Olanzapine

As prescribed by routine prescriber (not dictated by study protocol)

DRUG

Ziprasidone

As prescribed by routine prescriber (not dictated by study protocol)

DRUG

Quetiapine

As prescribed by routine prescriber (not dictated by study protocol)

DRUG

Aripiprazole

As prescribed by routine prescriber (not dictated by study protocol)

Sponsors & Collaborators

Principal Investigators

  • Susan M. Essock, PhD · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Primary Completion
2009-03-31
Completion
2009-03-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00044655 on ClinicalTrials.gov